Domain Therapeutics secured nearly €10M from the French National Research Agency via the "Hospital-University Health Research SPRINT Alliance" in January, to advance precision medicine and bring their lead drug DT-7012 to clinical trials.
Celltrion USA has finalized their application for a biologic license to the U.S. Food and Drug Administration for CT-P39, their alternative biosimilar to XOLAIR (omalizumab).
Wegovy® receives green light in the USA to diminish heart-related health hazards for those excessively heavy or with obesity coupled with confirmed heart conditions.
Eli Lilly and Company announced that the FDA will convene its Advisory Committee to discuss Phase 3 results of the TRAILBLAZER-ALZ 2 study on the efficacy and safety of donanemab in early Alzheimer's.